Evotec Leverages Infectious Diseases Space With Sanofi R&D Deal

Evotec's CEO tells Scrip its pact with Sanofi to develop an infectious disease pipeline could offer a commercially viable approach to battling the global AMR crisis.

Infectious diseases
Pact aims to accelerate drug discovery to combat Infectious diseases • Source: Shutterstock

By partnering with German biotech Evotec AG, Sanofi has increased its options for finding viable drugs against infectious diseases at a lower cost than if it did it on its own, the German biotech's CEO told Scrip.

Werner Lanthaler also said it's an avenue that other big pharma companies should explore if they are serious about helping...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip